CNAT - コナタス・ファ―マシュ―ティカルズ (Conatus Pharmaceuticals Inc.)

CNATのニュース

   Is Conatus Pharmaceuticals Inc.'s (NASDAQ:CNAT) CEO Paid Enough Relative To Peers?  2019/11/03 13:22:39 ACI Information Group
In 2005 Steven Mento was appointed CEO of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). First, this article will compare…
   Caspase 3 Market Comprehensive Study by Leading Players- Aptose Biosciences, BeyondSpring Pharmaceuticals, Conatus Pharmaceuticals  2019/11/02 09:57:00 MarketWatch
Nov 02, 2019 (HTF Market Intelligence via COMTEX) -- An extensive analysis of the Global Caspase 3 market strategy of the leading companies in the precision…
   Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know  2019/08/19 13:00:08 Zacks Investment Research
Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies  2019/08/07 10:00:00 Zacks Investment Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.
   Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates  2019/08/06 23:25:10 Zacks Investment Research
Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Is Conatus Pharmaceuticals Inc.'s (NASDAQ:CNAT) CEO Paid Enough Relative To Peers?  2019/11/03 13:22:39 ACI Information Group
In 2005 Steven Mento was appointed CEO of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). First, this article will compare…
   Caspase 3 Market Comprehensive Study by Leading Players- Aptose Biosciences, BeyondSpring Pharmaceuticals, Conatus Pharmaceuticals  2019/11/02 09:57:00 MarketWatch
Nov 02, 2019 (HTF Market Intelligence via COMTEX) -- An extensive analysis of the Global Caspase 3 market strategy of the leading companies in the precision…
   Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know  2019/08/19 13:00:08 Zacks Investment Research
Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies  2019/08/07 10:00:00 Zacks Investment Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.
   Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates  2019/08/06 23:25:10 Zacks Investment Research
Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

calendar